Interferon-γ activates transglutaminase 2 via a phosphatidylinositol- 3-kinase-dependent pathway: Implications for celiac sprue therapy

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 1, 2012, Pages 104-114

  DiRaimondo, Thomas R ^a   Klöck, Cornelius ^b   Khosla, Chaitan ^a,b  

^a Stanford University   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; BIM 11; DORSOMORPHIN; ERW1041E; GAMMA INTERFERON; GLUTEN; GLYCYL H 1152; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TRICIRIBINE; UNCLASSIFIED DRUG;

ARTICLE; CELIAC DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; PATHOGENESIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; RADIOIMMUNOPRECIPITATION; SMALL INTESTINE; T LYMPHOCYTE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; CELIAC DISEASE; CELL LINE; ENTEROCYTES; ENZYME ACTIVATION; GTP-BINDING PROTEINS; HUMANS; INTERFERON-GAMMA; MOLECULAR SEQUENCE DATA; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; TRANSGLUTAMINASES;

EID: 84858643071     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.187385     Document Type: Article

References (59)

1. Abadie V, Sollid LM, Barreiro LB, and Jabri B (2011) Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annu Rev Immunol 29:493-525.
2. Alaedini A and Green PH (2008) Autoantibodies in celiac disease. Autoimmunity 41:19-26.
3. Anderson RP, Degano P, Godkin AJ, Jewell DP, and Hill AV (2000) In vivo antigen challenge in celiac disease identifies a single transglutaminase- modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 6:337-342. (Pubitemid 30148628)
4. Beaurepaire C, Smyth D, and McKay DM (2009) Interferon-γ regulation of intestinal epithelial permeability. J Interferon Cytokine Res 29:133-144.
5. Bethune MT, Crespo-Bosque M, Bergseng E, Mazumdar K, Doyle L, Sestak K, Sollid LM, and Khosla C (2009a) Noninflammatory gluten peptide analogs as biomarkers for celiac sprue. Chem Biol 16:868-881.
6. Bethune MT, Siegel M, Howles-Banerji S, and Khosla C (2009b) Interferon-γ released by gluten-stimulated celiac disease-specific intestinal T cells enhances the transepithelial flux of gluten peptides. J Pharmacol Exp Ther 329:657-668.
7. Biagi F, Campanella J, Laforenza U, Gastaldi G, Tritto S, Grazioli M, Villanacci V, and Corazza GR (2006) Transglutaminase 2 in the enterocytes is coeliac specific and gluten dependent. Dig Liver Dis 38:652-658. (Pubitemid 44356273)
8. Bjarnason I and Peters TJ (1984) In vitro determination of small intestinal permeability: demonstration of a persistent defect in patients with coeliac disease. Gut 25:145-150. (Pubitemid 14131407)
9. Boivin MA, Roy PK, Bradley A, Kennedy JC, Rihani T, and Ma TY (2009) Mechanism of interferon-γ-induced increase in T84 intestinal epithelial tight junction. J Interferon Cytokine Res 29:45-54.
10. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, and Nusrat A (2003) Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 171:6164-6172. (Pubitemid 37467239)
11. Bruewer M, Utech M, Ivanov AI, Hopkins AM, Parkos CA, and Nusrat A (2005) Interferon-γ induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. FASEB J 19:923-933. (Pubitemid 40827713)
12. Chiorean EG, Mahadevan D., Harris WB, Von Hoff DD, Younger AE, Rensvold DM, Shelton CF, Hennessy BT, Garlich JR, and Ramanathan RK (2009) Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J Clin Oncol 27 (Suppl):122s.
13. Choudhury GG (2004) A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase Cε, and MAPK in mesangial cells regulates interferon-γ-induced STAT1 transcriptional activation. J Biol Chem 279:27399-27409.
14. De Re V, Simula, M.P. Notarpietro A, Canzonieri V, Cannizzaro R, and Toffoli G. (2010) Do gliadin and tissue transglutaminase mediate PPAR downregulation in intestinal cells of patients with coeliac disease? Gut 59:1730-1731.
15. Dicke WK, Weijers HA, and Van De Kamer JH (1953) Coeliac disease. II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease. Acta Paediatr 42:34-42.
16. Esposito C, Paparo F, Caputo I, Porta R, Salvati VM, Mazzarella G, Auricchio S, and Troncone R (2003) Expression and enzymatic activity of small intestinal tissue transglutaminase in celiac disease. Am J Gastroenterol 98:1813-1820. (Pubitemid 36959163)
17. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, et al. (2008) The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51:5522-5532.
18. Garcia-Echeverria C and Sellers WR (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27:5511-5526.
19. Green PH and Cellier C (2007) Celiac disease. N Engl J Med 357:1731-1743.
20. Green PH and Jabri B (2006) Celiac disease. Annu Rev Med 57:207-221. (Pubitemid 43261988)
21. Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Okada M, Ohta M, Tsukamoto S, Parker P, Workman P, et al. (2006) Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 14:6847-6858. (Pubitemid 44307656)
22. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, et al. (2005) PI 3-kinase p110β: a new target for antithrombotic therapy. Nat Med 11: 507-514. (Pubitemid 40685973)
23. Jabri B, Kasarda DD, and Green PH (2005) Innate and adaptive immunity: the yin and yang of celiac disease. Immunol Rev 206:219-231. (Pubitemid 41105173)
24. Jabri B and Sollid LM (2009) Tissue-mediated control of immunopathology in coeliac disease. Nat Rev Immunol 9:858-870.
25. Kagnoff MF (2007) Celiac disease: pathogenesis of a model immunogenetic disease. J Clin Invest 117:41-49.
26. Karell K, Louka AS, Moodie SJ, Ascher H, Clot F, Greco L, Ciclitira PJ, Sollid LM, Partanen J, and European Genetics Cluster on Celiac Disease (2003) HLA types in celiac disease patients not carrying the DQA1*05- DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol 64:469-477. (Pubitemid 36373778)
27. Komander D, Kular GS, Schüttelkopf AW, Deak M, Prakash KR, Bain J, Elliott M, Garrido-Franco M, Kozikowski AP, Alessi DR, et al. (2004) Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1. Structure 12:215-226. (Pubitemid 38224545)
28. Kong D and Yamori T (2009) Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem 16:2839-2854.
29. Luciani A, Villella VR, Vasaturo A, Giardino I, Pettoello-Mantovani M, Guido S, Cexus ON, Peake N, Londei M, Quaratino S, et al. (2010) Lysosomal accumulation of gliadin p31-43 peptide induces oxidative stress and tissue transglutaminase-mediated PPARγ downregulation in intestinal epithelial cells and coeliac mucosa. Gut 59:311-319.
30. Madara JL and Stafford J (1989) Interferon-γ directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 83:724-727. (Pubitemid 19061198)
31. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7:1851-1863.
32. McKay DM, Watson JL, Wang A, Caldwell J, Prescott D, Ceponis PM, Di Leo V, and Lu J (2007) Phosphatidylinositol 3′-kinase is a critical mediator of interferon-γ-induced increases in enteric epithelial permeability. J Pharmacol Exp Ther 320:1013-1022. (Pubitemid 46294056)
33. Molberg O, Mcadam SN, Körner R, Quarsten H, Kristiansen C, Madsen L, Fugger L, Scott H, Norén O, Roepstorff P, et al. (1998) Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 4:713-717. (Pubitemid 28274673)
34. Nava P, Koch S, Laukoetter MG, Lee WY, Kolegraff K, Capaldo CT, Beeman N, Addis C, Gerner-Smidt K, Neumaier I, et al. (2010) Interferon-γ regulates intestinal epithelial homeostasis through converging β-catenin signaling pathways. Immunity 32:392-402.
35. Nilsen EM, Jahnsen FL, Lundin KE, Johansen FE, Fausa O, Sollid LM, Jahnsen J, Scott H, and Brandtzaeg P (1998) Gluten induces an intestinal cytokine response strongly dominated by interferon γ in patients with celiac disease. Gastroenterology 115:551-563. (Pubitemid 28397290)
36. Nilsen EM, Lundin KE, Krajci P, Scott H, Sollid LM, and Brandtzaeg P (1995) Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon γ. Gut 37:766-776.
37. Pappenheimer JR, Dahl CE, Karnovsky ML, and Maggio JE (1994) Intestinal absorption and excretion of octapeptides composed of D amino acids. Proc Natl Acad Sci U S A 91:1942-1945. (Pubitemid 24080322)
38. Pappenheimer JR, Karnovsky ML, and Maggio JE (1997) Absorption and excretion of undegradable peptides: role of lipid solubility and net charge. J Pharmacol Exp Ther 280:292-300. (Pubitemid 27171415)
39. Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M, Chabert C, et al. (2006) Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ. J Med Chem 49:3857-3871. (Pubitemid 43967883)
40. Sadhu C, Masinovsky B, Dick K, Sowell CG, and Staunton DE (2003) Essential role of phosphoinositide 3-kinase Δ in neutrophil directional movement. J Immunol 170:2647-2654. (Pubitemid 36245657)
41. Samarin SN, Ivanov AI, Flatau G, Parkos CA, and Nusrat A (2007) Rho/Rho-associated kinase-II signaling mediates disassembly of epithelila apical junctions. Mol Biol Cell 18:3429-3439. (Pubitemid 47378682)
42. Scharl M, Paul G, Barrett KE, and McCole DF (2009) AMP-activated protein kinase mediates the interferon-γ-induced decrease in intestinal epithelial barrier function. J Biol Chem 284:27952-27963.
43. Shan L, Molberg Ø, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, and Khosla C (2002) Structural basis for gluten intolerance in celiac sprue. Science 297:2275-2279.
44. Siegel M and Khosla C (2007) Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 115:232-245. (Pubitemid 47042912)
45. Siegel M, Strnad P, Watts RE, Choi K, Jabri B, Omary MB, and Khosla C (2008) Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS ONE 3:e1861.
46. Smecuol E, Bai JC, Vazquez H, Kogan Z, Cabanne A, Niveloni S, Pedreira S, Boerr L, Mauriño E, and Meddings JB (1997) Gastrointestinal permeability in celiac disease. Gastroenterology 112:1129-1136. (Pubitemid 27157523)
47. Sollid LM and Khosla C (2011) Novel therapies for coeliac disease. J Intern Med 269:604-613.
48. Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, and Thorsby E.M. (1989) Evidence for a primary association of celiac disease to a particular HLA-DQ α/β heterodimer. J Exp Med 169:345-350. (Pubitemid 19035567)
49. Song JC, Hanson CM, Tsai V, Farokhzad OC, Lotz M, and Matthews JB (2001) Regulation of epithelial transport and barrier function by distinct protein kinase C isoforms. Am J Physiol Cell Physiol 281:C649-C661.
50. Stamnaes J, Pinkas DM, Fleckenstein B, Khosla C, and Sollid LM (2010) Redox regulation of transglutaminase 2 activity. J Biol Chem 285:25402-25409.
51. Tamura M, Nakao H, Yoshizaki H, Shiratsuchi M, Shigyo H, Yamada H, Ozawa T, Totsuka J, and Hidaka H (2005) Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta 1754:245-252. (Pubitemid 41797705)
52. Utech M, Ivanov AI, Samarin SN, Bruewer M, Turner JR, Mrsny RJ, Parkos CA, and Nusrat A (2005) Mechanism of IFN-γ-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. Mol Biol Cell 16:5040-5052. (Pubitemid 41416480)
53. van de Wal Y, Kooy Y, van Veelen P, Peña S, Mearin L, Papadopoulos G, and Koning F (1998) Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 161:1585-1588. (Pubitemid 28387571)
54. Vlahos CJ, Matter WF, Hui KY, and Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1benzopyran-4-one (LY294002). J Biol Chem 269:5241-5248.
55. Watts RE, Siegel M, and Khosla C (2006) Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles. J Med Chem 49:7493-7501. (Pubitemid 44913408)
56. Xia J, Siegel M, Bergseng E, Sollid LM, and Khosla C (2006) Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from α2-gliadin. J Am Chem Soc 128:1859-1867. (Pubitemid 43277324)
57. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, et al. (2005) Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cell overexpressing Akt. Cancer Res 64:4394-4399. (Pubitemid 38856907)
58. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174. (Pubitemid 32995375)
59. Zolotarevsky Y, Hecht G, Koutsouris A, Gonzalez DE, Quan C, Tom J, Mrsny RJ, and Turner JR (2002) A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 123:163-172. (Pubitemid 34747537)